Arbutus Biopharma Corp
imdusiran
chronic hepatitis B
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews imdusiran for chronic hepatitis B around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 12h ago
“The FDA’s Fast Track program is designed to facilitate the development and expedite the review of investigational therapies to treat serious conditions with unmet medical need.”